Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00588302 · ClinicalTrials.gov registry record · Phase 2
Moexipril for Primary Biliary Cirrhosis
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00588302: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT00588302 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00588302, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The blockade of angiotensin II synthesis attenuates hepatic fibrosis in different experimental models of chronic liver injury. We aimed to determine the safety and efficacy of moexipril, an angiotensin-converting enzyme (ACE) inhibitor, on liver biochemistries, Mayo risk score, and health-related quality of life in patients with primary biliary cirrhosis (PBC) who have had a suboptimal response to ursodeoxycholic acid (UDCA).
Interventions
- DRUG Moexipril
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2003-06 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00588302
The ClinicalTrials.gov registry entry for NCT00588302 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Moexipril is the first listed.
NCT00588302 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00588302 about?
NCT00588302 is a clinical study titled "Moexipril for Primary Biliary Cirrhosis". The blockade of angiotensin II synthesis attenuates hepatic fibrosis in different experimental models of chronic liver injury. We aimed to determine the safety and efficacy of moexipril, an angiotensin-converting enzyme (ACE) inhibitor, on liver biochemistries, Mayo risk score, and health-related qu...
What is the current status of trial NCT00588302?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2003-06. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00588302?
The interventions under investigation include: Moexipril (DRUG).
Who is sponsoring clinical trial NCT00588302?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.